Replies to post #180767 on Biotech Values

[DewDiligence]

(AMGN/NVS)—Neupogen FoB case illustrates complexity of 351(k) patent-exchange process:

http://www.fdalawblog.net/fda_law_blog_hyman_phelps/2014/10/feeling-dissed-amgen-sues-after-sandoz-abandons-the-bpcia-patent-dance-procedures-for-neupogen-biosi.html